<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03246685</url>
  </required_header>
  <id_info>
    <org_study_id>BT-CL-PGG-HNC-1622MK3475PN-544</org_study_id>
    <nct_id>NCT03246685</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Imprime PGG &amp; Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD</brief_title>
  <official_title>A Multicenter, Open-label, Phase 2 Study of Imprime PGG &amp; Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&amp;N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HiberCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HiberCell, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in&#xD;
      subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To&#xD;
      characterize the safety of Imprime PGG + pembrolizumab given in combination Hypothesis:&#xD;
      Restore (for subjects who have failed pembrolizumab mono therapy) or enhance (for subjects&#xD;
      who actively experiencing SD) sensitivity to checkpoint inhibitors (CPI) by appropriate and&#xD;
      effective stimulation of the subject's innate and adaptive immune systems by combining&#xD;
      Imprime PGG with pembrolizumab.&#xD;
&#xD;
      The study will require documenting at least 5 objective responses among the 38 subjects&#xD;
      enrolled who have failed prior pembrolizumab monotherapy and at least 17 objective responses&#xD;
      among the 49 subjects enrolled who are actively experiencing stable disease following at&#xD;
      least 4 cycles (but no more than 8 cycles) of pembrolizumab monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to enrollment challenges resulting in changing treatment patterns, the study has been&#xD;
    terminated. No patients remain on study.&#xD;
  </why_stopped>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">April 13, 2018</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) to Imprime PGG + pembrolizumab using RECIST v1.1 criteria</measure>
    <time_frame>Within 18 months of last patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) using RECIST v1.1 criteria</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR) using RECIST v1.1 criteria</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DoR) using RECIST v1.1 criteria</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) and PFS rate at 6 months and 1 year using RECIST v1.1 criteria</measure>
    <time_frame>6 months and 1 year after first dose and within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) and OS rate at 1 year</measure>
    <time_frame>1 year after first dose and within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) concentration for Imprime PGG and Pembrolizumab</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>ORR based on irRECIST</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>PFS based on irRECIST</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlate levels of baseline serum anti-β-glucan antibody (ABA) with objective response and treatment outcomes</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlate changes in immune cell activation markers, such as CD86 expression in tumor biopsy samples and in peripheral blood immune cells with objective response and treatment outcome</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In tumor biopsies, correlate changes in the tumor immune microenvironment including TILs (Tumor-infiltrating Lymphocytes) and tumor-infiltrating myeloid cells with objective response and treatment outcome</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlate PD-L1 expression in tumor biopsy samples (in tumor cells and myeloid cells) with objective response and treatment outcome</measure>
    <time_frame>Within 24 months of last patient enrolled</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Failures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imprime PGG + Pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Stable Disease on Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imprime PGG + Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Imprime PGG</intervention_name>
    <description>Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.</description>
    <arm_group_label>Active Stable Disease on Pembrolizumab</arm_group_label>
    <arm_group_label>Pembrolizumab Failures</arm_group_label>
    <other_name>Imprime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.</description>
    <arm_group_label>Active Stable Disease on Pembrolizumab</arm_group_label>
    <arm_group_label>Pembrolizumab Failures</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have signed an informed document prior to any study-specific procedures or treatment&#xD;
&#xD;
          2. Be ≥ 18 years of age at time of consent&#xD;
&#xD;
          3. Have histologically or cytologically confirmed diagnosis of SCCHN irrespective of&#xD;
             PD-L1 status, which is either inoperable and recurrent, or metastatic&#xD;
&#xD;
          4. Up to 3 prior chemotherapy regimens or metastatic disease&#xD;
&#xD;
          5. Have either:&#xD;
&#xD;
               1. Investigator determined assessment of disease progression after treatment with&#xD;
                  pembrolizumab monotherapy, OR&#xD;
&#xD;
               2. Investigator determined assessment of current stable disease following completion&#xD;
                  of at least 4 cycles but no more than 8 cycles, of pembrolizumab monotherapy&#xD;
&#xD;
          6. Have resolution of all previous treatment-related toxicities to Grade 1 severity or&#xD;
             lower, except for stable sensory neuropathy (less than or equal to Grade 2) or&#xD;
             alopecia. If subject received major surgery or radiation therapy of &gt; 30 Gy, must have&#xD;
             recovered from the toxicity and/or complications from the intervention.&#xD;
&#xD;
          7. Have at least one radiologically measurable lesion as per RECIST v1.1 defined as a&#xD;
             lesion that is at least 10 mm in longest diameter or lymph node that is at least 15 mm&#xD;
             in short axis imaged by CT scan or MRI and obtained by imaging within 28 days prior to&#xD;
             start of study treatment. Tumor lesions situated in a previously irradiated area are&#xD;
             considered measurable if progression has been demonstrated in such lesions.&#xD;
&#xD;
          8. Have peripheral blood levels of IgG anti-β-glucan antibody (ABA) of ≥ 20 mcg/mL as&#xD;
             determined by an ELISA test within 90 days prior to start of study treatment&#xD;
&#xD;
          9. Be willing to consider providing fresh tissue for biomarker analysis, and, based on&#xD;
             the adequacy of the tissue sample quality, for assessment of biomarker status. Repeat&#xD;
             samples may be required if adequate tissue is not provided. Newly obtained biopsy&#xD;
             specimens are preferred to archived samples and formalin-fixed, paraffin-embedded&#xD;
             block specimens are preferred to slides.&#xD;
&#xD;
             Note: Information on 1 tumor biopsy sample is mandatory and is as follows: (1) To&#xD;
             determine eligibility, historical (diagnostic) tumor biopsy official pathology report&#xD;
             +/- an archival sample. Additional biopsy samples, preferably obtained from the same&#xD;
             localized region, are highly desirable when feasible at the following time points: (2)&#xD;
             Sample before the first dose of study treatment, (3) Sample after completion of Cycle&#xD;
             2 but before the start of Cycle 3 dosing, and (4) Sample either at the time of&#xD;
             response or at the End of Study Visit (if no response).&#xD;
&#xD;
         10. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see&#xD;
             Appendix 14.3)&#xD;
&#xD;
         11. Have life expectancy of 6 months or greater as determined by the treating physician&#xD;
&#xD;
         12. Have adequate organ function (all screening labs should be performed within 15 days&#xD;
             prior to study treatment):&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) OR direct bilirubin ≤ ULN for&#xD;
                  subjects with total bilirubin levels &gt; 1.5 x ULN&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known&#xD;
                  hepatic metastases&#xD;
&#xD;
               3. Alanine aminotransferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known&#xD;
                  hepatic metastases&#xD;
&#xD;
               4. Albumin level ≥3 g/dL&#xD;
&#xD;
         13. Have adequate renal function within 15 days prior to study treatment, defined by the&#xD;
             following criteria:&#xD;
&#xD;
             Creatinine ≤ 1.5 x ULN and CrCl ≥ 30 ml/min per Cockcroft Gault formula:&#xD;
&#xD;
         14. Have adequate hematologic function within 15 days prior to study treatment, defined as&#xD;
             meeting all of the following criteria:&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g/dL (uncorrected by RBC transfusion)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L&#xD;
&#xD;
               3. Platelet count ≥ 100 × 109/L&#xD;
&#xD;
         15. Have adequate coagulation functioning within 15 days prior to start of study&#xD;
             treatment, defined by either of the following criteria:&#xD;
&#xD;
               1. INR &lt; 1.5 × ULN&#xD;
&#xD;
               2. OR for subjects receiving warfarin or low molecular weight heparin (LMWH), the&#xD;
                  subjects must, in the Investigator's opinion, be clinically stable with no&#xD;
                  evidence of active bleeding while receiving anticoagulant therapy. The INR for&#xD;
                  these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.&#xD;
&#xD;
               3. Activated Partial Thromboplastin Time (aPTT) &lt; 1.5 × ULN unless subject is&#xD;
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range&#xD;
                  of intended use of anticoagulants&#xD;
&#xD;
         16. Female subjects of childbearing potential as defined in Section 5.7.2 must have a&#xD;
             negative urine or serum pregnancy within 72 hours prior to receiving the first dose of&#xD;
             study medication. If the urine test is positive or cannot be confirmed as negative, a&#xD;
             serum pregnancy test will be required.&#xD;
&#xD;
         17. If of childbearing potential as defined in Section 5.7.2, must be willing to use an&#xD;
             adequate method of contraception (see Section 5.7.2) from the first dose of study&#xD;
             medication through 120 days after the last dose of study medication&#xD;
&#xD;
         18. Be willing and have the ability to comply with scheduled visits (including&#xD;
             geographical proximity), treatment plans, laboratory tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has disease that is suitable for local therapy administered with curative intent&#xD;
&#xD;
          2. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or receiving systemic steroid therapy (in dosing&#xD;
             exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive&#xD;
             therapy within 7 days prior to the first dose of study treatment. The use of&#xD;
             physiologic doses of corticosteroids may be approved after consultation with the&#xD;
             Sponsor.&#xD;
&#xD;
          4. Has known history of active tuberculosis&#xD;
&#xD;
          5. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)&#xD;
&#xD;
          6. Has known active Hepatitis B (eg, HBsAg reactive) or Hepatitis C (eg, HCV RNA&#xD;
             [qualitative] is detected&#xD;
&#xD;
          7. Has a history of clinically severe autoimmune disease, or history of organ transplant&#xD;
&#xD;
          8. Has known hypersensitivity to baker's yeast&#xD;
&#xD;
          9. Had previous exposure to Betafectin® or Imprime PGG&#xD;
&#xD;
         10. Has severe hypersensitivity to pembrolizumab or any of its excipients&#xD;
&#xD;
         11. Had a prior anti-cancer monoclonal antibody (other than pembrolizumab) within 30 days&#xD;
             prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better&#xD;
             from the adverse events of prior therapies&#xD;
&#xD;
         12. Had within 2 weeks prior to the first dose of study treatment, received prior&#xD;
             chemotherapy, targeted small molecule therapy, or radiation therapy, or who has not&#xD;
             recovered from adverse events due to a previously administered agent or major surgery&#xD;
&#xD;
         13. Has received transfusion of blood products (including platelets or red blood cells) or&#xD;
             administration of colony stimulating factors (including G-CSF, GM-CSF, or recombinant&#xD;
             erythropoietin) within 4 weeks prior to the first dose of study treatment&#xD;
&#xD;
         14. Has known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
         15. Has known active central nervous system metastases and/or carcinomatous meningitis.&#xD;
             Subjects with previously treated brain metastases may participate provided they are&#xD;
             stable (without evidence of progression by imaging for at least 4 weeks prior to the&#xD;
             first dose of trial treatment and any neurologic symptoms have returned to baseline),&#xD;
             have no evidence of new or enlarging brain metastases, and are not using steroids for&#xD;
             at least 7 days prior to trial treatment. This exception does not include&#xD;
             carcinomatous meningitis, which is excluded regardless of clinical stability.&#xD;
&#xD;
         16. Has active autoimmune disease requiring systemic treatment in the past 2 years (ie,&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).&#xD;
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteriod replacement&#xD;
             therapy for adrenal or pituitary insufficiency) is not considered a form of systemic&#xD;
             treatment.&#xD;
&#xD;
         17. Has history of (non-infectious) pneumonitis that required steroids or current&#xD;
             pneumonitis&#xD;
&#xD;
         18. Has a history of interstitial lung disease&#xD;
&#xD;
         19. Has an active infection requiring systemic therapy&#xD;
&#xD;
         20. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating Investigator&#xD;
&#xD;
         21. Has a clinically significant cardiovascular disease such as unstable angina,&#xD;
             myocardial infarction, or acute coronary syndrome within ≤180 days prior to start of&#xD;
             study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or&#xD;
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association&#xD;
             Functional Classification&#xD;
&#xD;
         22. Has a known psychiatric or substance abuse disorder(s) that would interfere with&#xD;
             informed consent or cooperation with the requirements of the trial&#xD;
&#xD;
         23. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment&#xD;
&#xD;
         24. Has received a live-virus vaccination within 30 days of planned treatment start.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 3, 2020</submitted>
    <returned>June 19, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03246685
org study id: BT-CL-PGG-HNC-1622MK3475PN-544
nct id: NCT03246685
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in
      subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To
      characterize the safety of Imprime PGG + pembrolizumab given in combination Hypothesis:
      Restore (for subjects who have failed pembrolizumab mono therapy) or enhance (for subjects
      who actively experiencing SD) sensitivity to checkpoint inhibitors (CPI) by appropriate and
      effective stimulation of the subject's innate and adaptive immune systems by combining
      Imprime PGG with pembrolizumab.

      The study will require documenting at least 5 objective responses among the 38 subjects
      enrolled who have failed prior pembrolizumab monotherapy and at least 17 objective responses
      among the 49 subjects enrolled who are actively experiencing stable disease following at
      least 4 cycles (but no more than 8 cycles) of pembrolizumab monotherapy.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Overall Response Rate (ORR) to Imprime PGG + pembrolizumab using RECIST v1.1 criteria
time frame: Within 18 months of last patient enrolled
measure: Time to response (TTR) using RECIST v1.1 criteria
time frame: Within 24 months of last patient enrolled
measure: Complete response rate (CRR) using RECIST v1.1 criteria
time frame: Within 24 months of last patient enrolled
measure: Duration of overall response (DoR) using RECIST v1.1 criteria
time frame: Within 24 months of last patient enrolled
measure: Progression-Free Survival (PFS) and PFS rate at 6 months and 1 year using RECIST v1.1 criteria
time frame: 6 months and 1 year after first dose and within 24 months of last patient enrolled
measure: Overall survival (OS) and OS rate at 1 year
time frame: 1 year after first dose and within 24 months of last patient enrolled
measure: Pharmacokinetic (PK) concentration for Imprime PGG and Pembrolizumab
time frame: Within 24 months of last patient enrolled
measure: ORR based on irRECIST
time frame: Within 24 months of last patient enrolled
measure: PFS based on irRECIST
time frame: Within 24 months of last patient enrolled
measure: Correlate levels of baseline serum anti-β-glucan antibody (ABA) with objective response and treatment outcomes
time frame: Within 24 months of last patient enrolled
measure: Correlate changes in immune cell activation markers, such as CD86 expression in tumor biopsy samples and in peripheral blood immune cells with objective response and treatment outcome
time frame: Within 24 months of last patient enrolled
measure: In tumor biopsies, correlate changes in the tumor immune microenvironment including TILs (Tumor-infiltrating Lymphocytes) and tumor-infiltrating myeloid cells with objective response and treatment outcome
time frame: Within 24 months of last patient enrolled
measure: Correlate PD-L1 expression in tumor biopsy samples (in tumor cells and myeloid cells) with objective response and treatment outcome
time frame: Within 24 months of last patient enrolled
arm group label: Pembrolizumab Failures
arm group type: Experimental
description: Imprime PGG + Pembrolizumab
arm group label: Active Stable Disease on Pembrolizumab
arm group type: Experimental
description: Imprime PGG + Pembrolizumab
intervention type: Biological
intervention name: Imprime PGG
description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
arm group label: Active Stable Disease on Pembrolizumab
arm group label: Pembrolizumab Failures
other name: Imprime
intervention type: Drug
intervention name: Pembrolizumab
description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
arm group label: Active Stable Disease on Pembrolizumab
arm group label: Pembrolizumab Failures
other name: Keytruda
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Carcinoma, Squamous Cell
mesh term: Squamous Cell Carcinoma of Head and Neck
mesh term: Pembrolizumab
submitted: June 3, 2020
returned: June 19, 2020